Quanergy Selected by PARIFEX as Exclusive Supplier of Long-Range 3D LiDAR for Highway Speed Detection and Enforcement
13.7.2021 13:00:00 EEST | Business Wire | Press release
Quanergy Systems, Inc., a leading provider of OPA-based solid state LiDAR sensors and smart 3D solutions for automotive and IoT, today announced that it has expanded its exclusive agreement with PARIFEX, a leading solution provider in project management for speed enforcement and smart cities, to deploy Quanergy’s M-Series 3D-LiDAR sensors for highway speed monitoring and enforcement. The new project will be deployed with the French Ministry of Interior, with future expansion to global projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005506/en/
Quanergy Selected by PARIFEX as Exclusive Supplier of Long-Range 3D LiDAR for Highway Speed Detection and Enforcement (Graphic: Business Wire)
The M8 LiDAR sensor from Quanergy features an extended range up to 200 meters and a superior angular beam resolution of 0.033 degrees, enabling highly accurate and reliable detection of speeding violations even in busy, fast-paced highway environments. The sensor will be integrated exclusively into the VIGIE Double-Side solutions by PARIFEX, an extra-urban speed control system able to track, identify and classify different vehicles simultaneously on different lanes and identify the speeding one through a picture of the front and the rear of the vehicle.
PARIFEX offers the only approved LiDAR-based system for speed measurement and control in France. Building on a multi-year partnership, this project will accelerate the goal of achieving safer highway systems.
“We have been committed to providing innovative and reliable solutions for many years to take part in the improvement of road safety, especially on fast highways,” said Franck Peyré, CEO at PARIFEX, “We chose Quanergy’s LiDAR for its accuracy to strengthen the VIGIE Double-Side solution, long-range detection at high speeds, as well as its high performance in challenging conditions. Our first project with Quanergy, which was deployed in Rouen France, confirmed our decision to continue leveraging Quanergy’s LiDAR technology in the VIGIE Double-Side.”
The fully automated, LiDAR-based VIGIE Double-Side monitors multiple lanes of traffic to detect, classify, and identify vehicles exceeding posted speed limits. This solution simultaneously measures the speed of all vehicles, and it can identify an offending vehicle from hundreds of meters upstream. The solution automatically classifies the category of vehicle (truck, passenger car, motorcycle, etc.) and adapts the speed threshold accordingly.
“From our first deployment in 2017, Quanergy and PARIFEX have worked together to leverage 3D LiDAR technology to make the world a safer place--one highway at a time,” said Enzo Signore, CMO at Quanergy, “This continuous deployment with PARIFEX is an important step towards a future with fewer road accidents.”
For more information, visit www.quanergy.com
About Quanergy Systems, Inc.
Quanergy Systems’ mission is to create powerful, affordable smart LiDAR solutions for automotive and IoT applications to enhance people’s experiences and safety. Quanergy has developed the only true 100% solid state CMOS LiDAR sensor built on optical phased array (OPA) technology to enable the mass production of low-cost, highly reliable 3D LiDAR solutions. Through Quanergy’s smart LiDAR solutions, businesses can now leverage real-time, advanced 3D insights to transform their operations in a variety of industries including industrial automation, physical security, smart cities, smart spaces, and much more. Quanergy solutions are deployed by over 350 customers across the globe. For more information, please visit us at www.quanergy.com.
About PARIFEX
PARIFEX is a leading solution provider in project management, helping its clients in all fields of activity in the conception, management, development, and integration of their great engineering projects in industry and road safety. Through its expertise, the company also designs leading solutions for projects such as smart cities, new mobility, and more. PARIFEX was founded in 1994 and has branches in Europe and Asia, along with clients throughout the world. For more information, visit www.parifex.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005506/en/
Contact information
Quanergy Media Contact
Neal Stein
Media@quanergy.com
PARIFEX Media Contact
Mélissa Guimaraes
mguimaraes@parifex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu
Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release
Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom